Education
About Us
Working with TipRanks
Follow Us
Clinigence Holdings (NUTX)
NASDAQ:NUTX
Top Page
Clinigence Holdings
(NASDAQ:NUTX)
Rating:73Outperform
Price Target:
$129.00
▲(13.27%Upside)
Positive Factors
Earnings
Nutex reported a 1Q beat with revenue of $211.9M, up 214% year over year.
Financial Performance
NUTX’s growing free cash flow from operations increased to $51.0M, which may support acceleration of expansion plans.
Growth Strategy
The company remains on track with its network expansion strategy, with three new micro-hospitals slated to open in Texas and a broader pipeline of seven De Novo facilities with targeted openings.
Negative Factors
Business Model Concerns
Shares currently trade at a discount to peers, reflecting the early stage and unproven nature of Nutex's business model.
Clinigence Holdings (NUTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$661.06M
Dividend YieldN/A
Average Volume (3M)152.62K
Price to Earnings (P/E)9.6
Beta (1Y)2.27
Revenue Growth141.25%
EPS GrowthN/A
CountryUS
Employees800
SectorHealthcare
Sector Strength48
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)2.56
Shares Outstanding5,555,116
10 Day Avg. Volume173,657
30 Day Avg. Volume152,620
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)125.66
Price to Sales (P/S)0.00
P/FCF Ratio334.85
Enterprise Value/Market Cap18.57
Enterprise Value/Revenue7.34
Enterprise Value/Gross Profit40.33
Enterprise Value/Ebitda32.75
Forecast
1Y Price Target
$262.50Price Target Upside130.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Clinigence Holdings Business Overview & Revenue Model
Company DescriptionClinigence Holdings (NUTX) is a healthcare technology company operating in the United States. The company focuses on providing data-driven solutions to improve healthcare delivery and outcomes. Its core products and services include advanced analytics, population health management, and value-based care solutions designed to support healthcare providers and organizations in optimizing their operations and enhancing patient care.
How the Company Makes MoneyClinigence Holdings makes money primarily through the sale of its technology solutions to healthcare providers and organizations. The company's revenue model includes subscription-based fees for its software platforms, which offer analytics and population health management tools. Additionally, Clinigence may generate income through consulting services and partnerships with healthcare providers who seek to implement value-based care initiatives. These revenue streams are supported by the company's ability to deliver actionable insights and data-driven strategies that help healthcare organizations improve efficiency and patient outcomes.
Clinigence Holdings Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q1-2025)
| % Change Since: -9.56%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant growth in patient visits, revenue, and profitability, alongside effective arbitration processes and expansion plans. However, challenges remain in the arbitration process and non-cash expenses impacting financials. Overall, positive progress was reported despite some ongoing challenges.Q1-2025 Updates
Positive Updates
Significant Increase in Patient Visits
Total patient visits reached 48,269, a 20.5% increase from 40,068 in Q1 2024. Mature hospitals achieved a 5.3% increase in visits.
Record Revenue Growth
Total revenue reached $211.8 million, a 214% increase from $67.5 million in Q1 2024. Hospital division revenue grew by 240%.
Strong Adjusted EBITDA and Net Income
Adjusted EBITDA was $72.8 million, up from a negative $400,000 in Q1 2024. Net income attributable to Nutex Health, Inc. was $14.6 million compared to a $400 million loss in Q1 2024.
Improved Cash Flow and Debt Reduction
Net cash flow from operating activities was $51 million compared to $3.1 million in Q1 2024. Long-term debt reduced to $20.7 million from $22.5 million at year-end 2024.
Effective Arbitration Process
Submitted 60% to 70% of billable visits through arbitration with an 80% win rate, increasing facility collections by 200% to 300% compared to initial insurance payments.
Expansion Plans
Plans to open three additional hospitals in 2025, with a pipeline extending to 2028 for more projects in high-demand markets.
Negative Updates
Challenges with Arbitration Process
Arbitration process still faces challenges with high costs and extended payment times. Only about 5% of eligible charts are arbitrated.
Non-Cash Stock-Based Compensation Expense
Accrued $36.1 million in non-cash stock-based compensation expense, impacting operating income figures.
Company Guidance
During Nutex Health's first-quarter 2025 earnings call, the company reported impressive financial growth and operational progress. Total patient visits increased by 20.5% to 48,269 compared to the previous year, with mature hospitals seeing a 5.3% rise in visits. Financially, the company achieved a 214% surge in total revenue, reaching $211.8 million, driven largely by their arbitration efforts, which contributed $105 million. Adjusted EBITDA rose to $72.8 million from a negative $400,000 in the previous year, while net income reached $14.6 million compared to a $400 million loss. Nutex's cash reserves grew significantly to $87.7 million, and their long-term debt decreased to $20.7 million. The company's focus on enhancing patient volume, optimizing revenue through efficient cycle management and arbitration, and maintaining cost discipline has positioned them well for continued growth. Looking ahead, Nutex plans to open three additional hospitals in 2025 and is considering further expansion through various strategic options, including de novo hospital openings and potential acquisitions.Clinigence Holdings Financial Statement Overview
Summary
Clinigence Holdings demonstrates solid financial performance with notable revenue growth and profitability improvements. While the company shows efficient operational cash flow management, the balance sheet highlights increased leverage, which could pose future risks.Income Statement
Clinigence Holdings shows strong revenue growth with a significant increase in total revenue on a TTM basis compared to previous periods. The gross profit margin has improved, indicating efficient cost management. Net profit margin is healthy, reflecting profitability. However, historical volatility in EBIT and EBITDA margins suggests potential instability.75
Positive
Balance Sheet
The balance sheet reflects moderate financial leverage with a debt-to-equity ratio that has increased, potentially raising risk. However, the return on equity is robust, signaling effective use of equity. Equity ratio is reasonable, indicating a stable asset base but with room for improvement in reducing liabilities.65
Positive
Cash Flow
Operating cash flow has improved significantly, supporting a positive free cash flow trajectory. The operating cash flow to net income ratio suggests strong operational efficiency. However, historical fluctuations in free cash flow growth underscore potential variability in cash management.70
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 624.28M | 479.95M | 247.65M | 219.29M | 331.53M | 273.42M | Gross Profit |
| 304.44M | 196.26M | 34.77M | 13.45M | 179.28M | 271.60M | EBIT |
| 201.38M | 130.62M | -31.77M | -5.14M | 170.26M | 152.33M | EBITDA |
| 214.15M | 148.65M | -14.58M | -393.96M | 183.45M | -5.12M | Net Income Common Stockholders |
| 96.77M | 52.18M | -45.79M | -432.74M | 132.59M | 105.97M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 87.67M | 43.58M | 22.00M | 34.26M | 36.12M | 25.51M | Total Assets |
| 761.92M | 655.32M | 398.25M | 431.75M | 394.65M | 308.55M | Total Debt |
| 312.50M | 340.30M | 275.76M | 267.20M | 178.55M | 150.12M | Net Debt |
| 224.83M | 296.72M | 253.75M | 232.95M | 142.43M | 124.61M | Total Liabilities |
| 487.04M | 453.43M | 319.14M | 311.42M | 203.07M | 161.19M | Stockholders Equity |
| 274.88M | 146.34M | 61.45M | 95.86M | 114.65M | 85.81M |
| Cash Flow | Free Cash Flow | ||||
| 69.50M | 20.85M | -8.24M | 35.97M | 136.51M | 20.07M | Operating Cash Flow |
| 71.07M | 23.15M | 1.26M | 50.61M | 173.43M | 81.26M | Investing Cash Flow |
| -2.00M | -2.67M | -11.24M | -4.34M | -36.98M | -61.19M | Financing Cash Flow |
| -11.41M | 1.09M | -2.27M | -48.13M | -125.85M | -2.56M |
Clinigence Holdings Technical Analysis
Negative
113.89
Price Trends
136.81
Negative
96.47
Positive
62.44
Positive
Market Momentum
-6.10
Positive
39.24
Neutral
23.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Negative. The current price of 113.89 is below the 20-day moving average (MA) of 138.32, below the 50-day MA of 136.81, and above the 200-day MA of 62.44, indicating a neutral trend. The MACD of -6.10 indicates Positive momentum. The RSI at 39.24 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUTX.
Clinigence Holdings Risk Analysis
Clinigence Holdings disclosed 62 risk factors in its most recent earnings report. Clinigence Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clinigence Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $661.06M | 9.57 | 51.65% | ― | 141.25% | ― | |
60 Neutral | $329.11M | ― | -41.31% | ― | ― | -7.93% | |
53 Neutral | $5.24B | 3.32 | -44.36% | 6.63% | 16.78% | -0.12% | |
51 Neutral | $460.15M | ― | -79.51% | ― | -100.00% | 10.73% | |
51 Neutral | $460.04M | ― | 344.74% | ― | -47.32% | -26.67% | |
46 Neutral | $280.53M | ― | -41.59% | ― | ― | 0.42% | |
33 Underperform | $246.51M | ― | -98.14% | ― | ― | -33.79% |
* Healthcare Sector Average
Performance Comparison
NUTX
Clinigence Holdings
113.89
108.29
1933.75%
ATYR
aTyr Pharma
5.22
3.73
250.34%
IVA
Inventiva
3.29
0.62
23.22%
CMPX
Compass Therapeutics
2.40
1.30
118.18%
OLMA
Olema Pharmaceuticals
4.13
-7.50
-64.49%
CADL
Candel Therapeutics
4.75
-1.29
-21.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.